(Q44017116)

29 November 2017

title

Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation (English)

1 reference

29 November 2017

1 reference

lymphoblastic leukemia

1 reference

inferred from title

author

Frederick R. Appelbaum

7

object named as

Frederick R Appelbaum

1 reference

29 November 2017

2

Katherine A Guthrie

1 reference

29 November 2017

Derek L Stirewalt

1

1 reference

29 November 2017

Lan Beppu

3

1 reference

29 November 2017

Eileen M Bryant

4

1 reference

29 November 2017

Kris Doney

5

1 reference

29 November 2017

Ted Gooley

6

1 reference

29 November 2017

Jerald P Radich

8

1 reference

29 November 2017

language of work or name

1 reference

1 March 2003

1 reference

Biology of Blood and Marrow Transplantation

29 November 2017

published in

1 reference

29 November 2017

volume

9

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

206-212

1 reference

Structural organization of the bcr gene and its role in the Ph' translocation

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. Berlin-Frankfurt-Münster Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Second allogeneic transplantation after failure of first autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Marrow transplantation for the treatment of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

The Analysis of Failure Times in the Presence of Competing Risks

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1083-8791%2803%2970011-1

7 January 2021

10.1016/S1083-8791(03)70011-1

Identifiers

DOI

1 reference

29 November 2017

1 reference